Takeyuki Kono

Dr. Takeyuki Kono

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Clinical Nutrition
Verified
Journal Article
Closed access
TKTakeyuki Kono
Takeyuki Kono
KSKoji Sakamoto
Koji Sakamoto
SSSeiichi Shinden
Seiichi Shinden
KOKaoru Ogawa
Kaoru Ogawa

11 March 2016 in Head & Neck
Verified
Journal Article
Closed access
PDF file
TKTakeyuki Kono
Takeyuki Kono
KSKoichiro Saito
Koichiro Saito
HYHaruna Yabe
Haruna Yabe
KUKosuke Uno
Kosuke Uno
KOKaoru Ogawa
Kaoru Ogawa

14 March 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KKKen Kasahara
Ken Kasahara
TKTakeyuki Kono
Takeyuki Kono
YSYoichiro Sato
Yoichiro Sato
MUMasafumi Ueno
Masafumi Ueno
HSHirotaka So
Hirotaka So
HOHiroyuki Ozawa
Hiroyuki Ozawa
Objectives: Evaluation of sarcopenia accompanied by systemic inflammation status is a more beneficial prognostic marker than sarcopenia alone in various cancers. However, few studies have focused on this combination in patients with head and neck squamous cell cancer (HNSCC). In this study, we investigated how the combination of sarcopenia and systemic inflammation could affect survival in patients with HNSCC. Moreover, we explored which systemic inflammation markers could be better prognostic indicators when accompanied by sarcopenia.Materials and methods: We retrospectively reviewed the medical records of patients with HNSCC treated between 2012 and 2016. Sarcopenia was defined by the skeletal muscle area measured on a computed tomography image slice at the level of the third cervical vertebra. The neutrophil/lymphocyte, platelet/lymphocyte, and lymphocyte/monocyte ratios (NLR, PLR, and LMR, respectively) were used as systemic inflammation markers that were combined with sarcopenia to evaluate prognosis.Results: A total of 100 patients were enrolled, and 71 patients were considered sarcopenia. Patients with sarcopenia had significantly lower LMR and higher NLR and PLR. They also showed worse overall survival (OS) and progression-free survival (PFS). The comparative assessment of multiple combination patterns of sarcopenia and systemic inflammation indices proved that sarcopenia plus LMR considered as most reliable indicator for prognosis in HNSCC patients. Sarcopenia plus low LMR was a significantly poor prognostic factor both for OS and PFS with greater HR values than sarcopenia alone.Conclusions: The combination of sarcopenia and LMR was considered the most sensitive prognostic factor in patients with HNSCC, suggesting it might be beneficial for identifying poor outcome risks.

14 September 2021 in Viruses
Verified
Journal Article
Open access
PDF file
TKTakeyuki Kono
Takeyuki Kono
Laimonis LaiminsLaimonis Laimins
Laimonis Laimins
Human papillomaviruses (HPV) are the causative agents of cervical and other anogenital cancers as well as those of the oropharynx. HPV proteins activate host DNA damage repair factors to promote their viral life cycle in stratified epithelia. Activation of both the ATR pathway and the ATM pathway are essential for viral replication and differentiation-dependent genome amplification. These pathways are also important for maintaining host genomic integrity and their dysregulation or mutation is often seen in human cancers. The APOBEC3 family of cytidine deaminases are innate immune factors that are increased in HPV positive cells leading to the accumulation of TpC mutations in cellular DNAs that contribute to malignant progression. The activation of DNA damage repair factors may corelate with expression of APOBEC3 in HPV positive cells. These pathways may actively drive tumor development implicating/suggesting DNA damage repair factors and APOBEC3 as possible therapeutic targets.

23 April 2016 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
TKTakeyuki Kono
Takeyuki Kono
KSKoichiro Saito
Koichiro Saito
HYHaruna Yabe
Haruna Yabe
KOKaoru Ogawa
Kaoru Ogawa

28 July 2023 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
TKTakeyuki Kono
Takeyuki Kono
STShuta Tomisato
Shuta Tomisato
HOHiroyuki Ozawa
Hiroyuki Ozawa
Objectives: Vocal fold medialization surgery is generally considered a phonosurgical procedure for improvement of vocal function in patients with glottic insufficiency. However, the literature describing this procedure for the management of dysphagia is limited. This study aims to assess the effects of medialization surgery on swallowing function in patients with unilateral vocal fold paralysis (UVFP).Methods: We enrolled 32 patients with UVFP undergoing vocal fold medialization surgery (medialization laryngoplasty combined with arytenoid adduction [ML + AA], 12 cases; injection laryngoplasty [IL], 20 cases). We assessed the aerodynamic vocal function including maximum phonation time and mean flow rate to evaluate glottal closure status. The Hyodo score determined by flexible endoscopic evaluation and Functional Oral Intake Scale (FOIS) were evaluated pre‐ and postoperatively.Results: Almost 60% of patients with UVFP had dysphagia, and one‐third were at high risk for aspiration. Aerodynamic parameters effectively improved after IL and ML + AA. With regard to swallowing, both the FOIS and total Hyodo score were significantly improved postoperatively. We found a particularly significant improvement in pharyngeal clearance. However, patients with high vagal nerve paralysis and postoperative insufficient glottal closure showed poor swallowing benefits after the interventions. In patients with recurrent laryngeal nerve palsy, there were no significant differences in postoperative swallowing function between the ML + AA and IL groups.Conclusion: Vocal fold medialization surgery was effective in improving swallowing function in most cases with UVFP, except for those with high vagal paralysis and insufficient postoperative glottal closure. Both IL and ML + AA showed an equivalent effect on swallowing improvement.Level of evidence: 3b.